News & Updates

Problems with pain or discomfort continue to bother young adults with juvenile idiopathic arthritis (JIA) despite their constant use of medication, a study has shown.

A recent study has found that tapering methotrexate (MTX) from targeted therapy in patients with controlled rheumatoid arthritis (RA) is feasible, but this may result in a 10-percent decrease in the ability to sustain remission for up to 18 months.

Among patients with rheumatoid arthritis (RA), those with clinically active RA, cardiovascular or cerebrovascular disease (CVD), hypertension, depression, and anxiety are at greater risk of dementia, reveals a study. Among CVD events, ischaemic stroke and heart failure are significantly associated with an increased dementia risk.

YLB113, a biosimilar of the reference product etanercept, appears to be safe for long-term treatment of patients with rheumatoid arthritis, with efficacy sustained for up to 96 weeks, according to a study. Notably, the biosimilar is associated with fewer cases of injection-site reactions and injection-site erythema compared with the reference.

Co-treatment with methotrexate (MTX) appears to enhance response rates to pegloticase among patients with uncontrolled gout, according to a study.

Young patients with coeliac disease (CD) tend to develop juvenile idiopathic arthritis (JIA) three times more often than does the general population, while adult CD patients appear to have rheumatoid arthritis (RA) nearly twice as often, reveals a study.

Treatments used in rheumatoid arthritis, called disease-modifying antirheumatic drugs, can also lower the risk of heart disease among patients, as shown in a recent study.